File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

TitlePembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Authors
Kudo, MLim, HYCheng, ALChao, YYau, TCCOgasawara, SKurosaki, MMorimoto, NOhkawa, KYamashita, TLee, KHChen, ESiegel, ABRyoo, BY
Issue Date2020
PublisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487
Citation
Liver Cancer (Forthcoming) How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/289771
ISSN
2235-1795
2023 Impact Factor: 11.6
2023 SCImago Journal Rankings: 3.599

 

DC FieldValueLanguage
dc.contributor.authorKudo, M-
dc.contributor.authorLim, HY-
dc.contributor.authorCheng, AL-
dc.contributor.authorChao, Y-
dc.contributor.authorYau, TCC-
dc.contributor.authorOgasawara, S-
dc.contributor.authorKurosaki, M-
dc.contributor.authorMorimoto, N-
dc.contributor.authorOhkawa, K-
dc.contributor.authorYamashita, T-
dc.contributor.authorLee, KH-
dc.contributor.authorChen, E-
dc.contributor.authorSiegel, AB-
dc.contributor.authorRyoo, BY-
dc.date.accessioned2020-10-22T08:17:14Z-
dc.date.available2020-10-22T08:17:14Z-
dc.date.issued2020-
dc.identifier.citationLiver Cancer (Forthcoming)-
dc.identifier.issn2235-1795-
dc.identifier.urihttp://hdl.handle.net/10722/289771-
dc.languageeng-
dc.publisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487-
dc.relation.ispartofLiver Cancer-
dc.rightsLiver Cancer. Copyright © S. Karger AG.-
dc.rightsThis is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g., Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number]. OR This is the un-reviewed and unedited manuscript version of the following article: [insert full citation, e.g., Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].-
dc.titlePembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.hkuros316118-
dc.publisher.placeSwitzerland-
dc.identifier.issnl1664-5553-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats